Navigation Links
Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Date:8/27/2007

lty streams at competitive rates from companies, institutions and inventors. DRC is a leader in monetizing royalties, having acquired over $850 million in royalty-based cash flows on commercialized products.

Its Structured Finance Fund will soon close with approximately $300 million in committed capital. This Fund provides predominantly non-dilutive financing for product acquisitions and launches, M & A, in-licensing, sales force expansion and general working capital purposes to companies within the healthcare industry. The Fund invests in cash flow monetization structures which can include debt and equity components, custom tailored to fit the needs of clients.

About Enzon (ENZN)

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development, manufacturing, commercialization of important medicines for patients with cancer and other life-threatening conditions. Enzon has a portfolio of four marketed products, Oncaspar(R), DepoCyt(R), Abelcet(R) and Adagen(R). The Company's drug development programs utilize several cutting- edge approaches, including its industry-leading PEGylation technology platform used to create product candidates with benefits such as reduced dosing frequency and less toxicity. Enzon's PEGylation technology was used to develop two of its products, Oncaspar and Adagen, and has created a royalty revenue stream from licensing partnerships for other products developed using the technology. Enzon also engages in contract manufacturing for several pharmaceutical companies to broaden the Company's revenue base. Further information about Enzon can be found on the Company's web site at http://www.enzon.com.


'/>"/>
SOURCE Drug Royalty Corporation, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Trouble-shooting: Misincorporation or low fidelity
2. Roche Diagnostics Corporation
3. Roche Diagnostics Corporation
4. Promega Corporation: Wisconsins quiet innovator
5. Giuliani will keynote RedPrairie Corporations user conference
6. Madison Development Corporation makes loans to three area companies
7. Corporations and blogging
8. Metavante acquires Florida banking corporation
9. TriMas Corporations Cequent Group Acquires Chem-Chrome, Inc.
10. Speaker announces business members of IT Task Force
11. Doyle announces technology tax credits for Berbee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014 CSSi, the leader ... recently announced the formation of the company,s Medical and ... the addition of Dr. William E. Gannon, Jr. ... http://photos.prnewswire.com/prnh/20140818/136957 The MCAB, with Dr. ... of therapeutic areas and set strategic goals for the ...
(Date:8/19/2014)... , Aug. 19, 2014 /PRNewswire/ - iCo Therapeutics Inc. ... today reported results of its Oral Amphotericin B ... reservoirs.  The study, conducted by ImmuneCarta®, the immune ... vitro effectiveness of Oral Amp B in ... in individuals despite intensive treatment with antiretroviral therapy. ...
(Date:8/18/2014)... A new therapy developed by researchers at the ... Medicine and Columbia University Medical Center (CUMC) may ... disease treatment. , The researchers demonstrated in ... could selectively inhibit blood vessel re-narrowing and simultaneously ... a balloon catheter to open narrowed or blocked ...
(Date:8/18/2014)... Aug. 18, 2014   Sterne, Kessler, Goldstein & ... Washington, DC , announced today that ... Review (IPR) with the U.S. Patent and Trademark ... of BioReference Laboratories, Inc. (Nasdaq: BRLI).  These IPR petitions ... by Myriad Genetics, Inc. These patents have been asserted ...
Breaking Biology Technology:CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 2Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 3
... LONDON, Oct. 28 Chiltern, a leading global ... on this year,s,shortlist for the SCRIP Awards in ... be announced at the fourth annual SCRIP awards,ceremony ... Park Lane., "I am delighted that Chiltern ...
... of mammals, the protective shells of mollusks, and the needle-sharp ... wonders of nature. , Used to crush food, for structural ... and bones are composed are the strongest and most durable ... sought to mimic them. , Now, harnessing the process of ...
... Thomas Reidy, an investor in,Trinity Biotech plc (Nasdaq: ... whose American Depository Receipts are,traded on NASDAQ, will host ... to discuss the recent shareholder proposal calling for the,removal ... October 16, 2008, Mr. Reidy, and nine other shareholders, ...
Cached Biology Technology:Chiltern Is a Nominee on the SCRIP CRO of the Year Award Shortlist 2Sea urchin yields a key secret of biomineralization 2Sea urchin yields a key secret of biomineralization 3Investor Call Scheduled to Discuss Ouster Proposal of Trinity Biotech Directors 2
(Date:8/20/2014)... -  Issue Serious allergic reactions to ... threatening for some children.    What you should ... food allergies and this number may be increasing, especially among ... to have food allergies.  The symptoms of ... to breathing difficulties and loss of consciousness. Symptoms can also ...
(Date:8/20/2014)... visible in in this image of the Para and ... were most likely intentionally set in order to deforest ... or stand of trees where the land is thereafter ... conversion of forestland to farms, ranches, or urban use. ... of the Amazon Rainforest in the middle of the ...
(Date:8/20/2014)... 19, 2014 -- Bay Area Lyme Foundation, which aims ... to cure, applauds new research published in an upcoming ... and Tick-borne Diseases . The findings show that ... active throughout the year, making the threat of Lyme ... California Department of Public Health (CDPH) Vector-borne Disease Section ...
Breaking Biology News(10 mins):Information Update - Allergens and food safety at school - What's in your child's lunch? 2Information Update - Allergens and food safety at school - What's in your child's lunch? 3Lyme disease risk is year-round in Northwest California, according to new study 2Lyme disease risk is year-round in Northwest California, according to new study 3
... segments of the Pacific Ocean lack sufficient iron to ... mineral stresses these microscopic ocean plants, triggering them to ... robust than it really is. , As a result, ... the researchers say, and the tropical Pacific Ocean may ...
... of diagnosed diabetes in U.S. adults age 20 and older ... to researchers at the National Institutes of Health (NIH) and ... national survey data from two periods--1988 to 1994 and 1999 ... diabetes did not change significantly over the years studied. ...
... of atmospheric ozone -- which protects Earth from the ... in the most important regions of the stratosphere above ... a new study shows. , Researchers attribute the improvement ... by the global Montreal Protocol treaty and its amendments ...
Cached Biology News:Iron critical to ocean productivity, carbon uptake 2Iron critical to ocean productivity, carbon uptake 3One-third of adults with diabetes still don't know they have it 2One-third of adults with diabetes still don't know they have it 3One-third of adults with diabetes still don't know they have it 4Atmospheric ozone recovering in mid-latitudes, report shows 2Atmospheric ozone recovering in mid-latitudes, report shows 3Atmospheric ozone recovering in mid-latitudes, report shows 4
MOUSE ANTI RABBIT T LYMPHOCTYES Immunogen: Rabbit Thymocytes...
Normal canine serum collected from healthy normal canines....
RABBIT ANTI HUMAN CYTOCHROME P450 1A1/2 Immunogen: Purified human CYP1A2 expressed in E.Coli ...
... Error-free cloning of BAC (100+kb), fosmid ... Greater insert stability than any othe BAC ... for high yields and easy recombinant DNA ... or transcription-free (pSMART VC) vectors for the ...
Biology Products: